Creo Medical has reported its results for the 6 months to June 2023. As pre the recent trading update, revenues in the period were £15.7m, supported by growth from the Core Creo products and Endotherapy consumables. Gross profit increased, though gross margin declined marginally due to revenue mix. Creo’s cost base continues to fall supporting reduced operating losses. Cash at period end was £26.5m with £4.5m of R&D tax credits received post-period. The company expects to maintain its growth tra ....
